Alexion's Kanuma Fails To Impress NICE
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, says it is not recommending Alexion's Kanuma (sebelipase alfa) for one set of patients with lysosomal acid lipase deficiency, but wants more evidence when considering another group of patients with the same rare genetic disorder. The institute is concerned that the drug is not good value for the National Health Service, while Alexion says NICE has failed to recognize the Kanuma's "transformative innovation."
Register for our free email digests: